You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethadone
Accession NumberDB00333  (APRD00485)
TypeSmall Molecule
GroupsApproved
Description

A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Methadone is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3).

In Australia methadone is a Schedule 8 (controlled) drug.

Structure
Thumb
Synonyms
SynonymLanguageCode
(+-)-MethadoneNot AvailableNot Available
(+/-)-MethadoneNot AvailableNot Available
(±)-methadoneNot AvailableNot Available
6-Dimethylamino-4,4-diphenyl-3-heptanoneNot AvailableNot Available
dl-MethadoneNot AvailableNot Available
MethadonumNot AvailableNot Available
Salts
Name/CAS Structure Properties
Methadone Hydrochloride
1095-90-5
Thumb
  • InChI Key: FJQXCDYVZAHXNS-UHFFFAOYNA-N
  • Monoisotopic Mass: 345.18594223
  • Average Mass: 345.906
DBSALT000346
Brand names
NameCompany
AdolanNot Available
DepridolNot Available
DISKETSNot Available
DolophineNot Available
HeptadonNot Available
HeptanonNot Available
KetalginNot Available
MephenonNot Available
METHADOSENot Available
PhyseptoneNot Available
PolamidonNot Available
Brand mixturesNot Available
Categories
CAS number76-99-3
WeightAverage: 309.4452
Monoisotopic: 309.209264491
Chemical FormulaC21H27NO
InChI KeyUSSIQXCVUWKGNF-UHFFFAOYSA-N
InChI
InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
IUPAC Name
6-(dimethylamino)-4,4-diphenylheptan-3-one
SMILES
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassBenzenoids
ClassBenzene and Substituted Derivatives
SubclassDiphenylmethanes
Direct parentDiphenylmethanes
Alternative parentsPhenylpropylamines; Tertiary Amines; Ketones; Polyamines; Enolates
Substituentsphenylpropylamine; ketone; tertiary amine; enolate; polyamine; amine; organonitrogen compound; carbonyl group
Classification descriptionThis compound belongs to the diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Pharmacology
IndicationFor the treatment of dry cough, drug withdrawal syndrome, opioid type drug dependence, and pain.
PharmacodynamicsMethadone is a synthetic opioid analgesic with multiple actions quantitatively similar to those at morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, Methadone is more active and more toxic than morphine. Methadone is indicated for relief of severe pain, for detoxification treatment of narcotic addiction, and for temporary maintenance treatment of narcotic addiction. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The Methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.
Mechanism of actionMethadone is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The principal therapeutic uses for methadone are for analgesia and for detoxification or maintenance in opioid addiction. The methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown. Other NMDA receptor antagonists have been shown to produce neurotoxic effects in animals.
AbsorptionWell absorbed following oral administration. The bioavailability of methadone ranges between 36 to 100%.
Volume of distribution
  • 1.0 to 8.0 L/kg
Protein bindingIn plasma, methadone is predominantly bound to α1-acid glycoprotein (85% to 90%).
Metabolism

Hepatic. Cytochrome P450 enzymes, primarily CYP3A4, CYP2B6, and CYP2C19 and to a lesser extent CYP2C9 and CYP2D6, are responsible for conversion of methadone to EDDP and other inactive metabolites, which are excreted mainly in the urine.

SubstrateEnzymesProduct
Methadone
2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP)Details
2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP)
2-Ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP)Details
Route of eliminationThe elimination of methadone is mediated by extensive biotransformation, followed by renal and fecal excretion. Unmetabolized methadone and its metabolites are excreted in urine to a variable degree.
Half life24-36 hours
Clearance
  • 1.4 to 126 L/h
ToxicityIn severe overdosage, particularly by the intravenous route, apnea, circulatory collapse, cardiac arrest, and death may occur.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Methadone Metabolism PathwayDrug metabolismSMP00624
Methadone Action PathwayDrug actionSMP00408
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
Property Value Probability
Human Intestinal Absorption + 0.9968
Blood Brain Barrier + 0.9772
Caco-2 permeable + 0.7841
P-glycoprotein substrate Substrate 0.6224
P-glycoprotein inhibitor I Inhibitor 0.7627
P-glycoprotein inhibitor II Non-inhibitor 0.9101
Renal organic cation transporter Non-inhibitor 0.5851
CYP450 2C9 substrate Non-substrate 0.7822
CYP450 2D6 substrate Non-substrate 0.7743
CYP450 3A4 substrate Substrate 0.66
CYP450 1A2 substrate Inhibitor 0.5312
CYP450 2C9 substrate Non-inhibitor 0.864
CYP450 2D6 substrate Inhibitor 0.5449
CYP450 2C19 substrate Non-inhibitor 0.8177
CYP450 3A4 substrate Non-inhibitor 0.5507
CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6586
Ames test Non AMES toxic 0.946
Carcinogenicity Carcinogens 0.6315
Biodegradation Not ready biodegradable 0.9888
Rat acute toxicity 3.5250 LD50, mol/kg Not applicable
hERG inhibition (predictor I) Weak inhibitor 0.947
hERG inhibition (predictor II) Inhibitor 0.7606
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Vistapharm inc
  • Mallinckrodt chemical inc
  • Bioniche pharma usa llc
  • Sandoz inc
  • Mallinckrodt inc
  • The pharmanetwork llc
Packagers
Dosage forms
FormRouteStrength
LiquidOral
SolutionOral
TabletOral
Prices
Unit descriptionCostUnit
Methadone hcl 10 mg/ml vial7.48USDml
Methadone hcl powder5.91USDg
Metadol 25 mg Tablet1.69USDtablet
Metadol 10 mg Tablet0.9USDtablet
Methadone intensol 10 mg/ml0.85USDml
Metadol 5 mg Tablet0.56USDtablet
Methadone hcl 10 mg tablet0.37USDtablet
Metadol Concentrate 10 mg/ml Liquid0.37USDml
Methadone hcl 5 mg tablet0.34USDtablet
Dolophine hcl 10 mg tablet0.21USDtablet
Metadol 1 mg Tablet0.17USDtablet
Methadose 5 mg tablet0.16USDtablet
Methadose 10 mg tablet0.14USDtablet
Dolophine hcl 5 mg tablet0.13USDtablet
Metadol 1 mg/ml Solution0.1USDml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Statesolid
Experimental Properties
PropertyValueSource
melting point235.0 °CNot Available
logP3.93HANSCH,C ET AL. (1995)
pKa8.94 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility0.0059ALOGPS
logP4.14ALOGPS
logP5.01ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)18.78ChemAxon
pKa (Strongest Basic)9.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.27 m3·mol-1ChemAxon
Polarizability36.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Spectra
Spectra
References
Synthesis Reference

Charles J. Barnett, “Modification of methadone synthesis process step.” U.S. Patent US4048211, issued August, 1952.

US4048211
General Reference
  1. Kell MJ: Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting. J Addict Dis. 1994;13(1):5-26. Pubmed
  2. Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. Pubmed
  3. Joseph H, Stancliff S, Langrod J: Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000 Oct-Nov;67(5-6):347-64. Pubmed
  4. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. Pubmed
  5. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL: Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005 Oct;100(10):1496-509. Pubmed
External Links
ResourceLink
KEGG CompoundC07163
PubChem Compound4095
PubChem Substance46505722
ChemSpider3953
ChEBI6807
ChEMBLCHEMBL651
Therapeutic Targets DatabaseDAP000267
PharmGKBPA450401
Drug Product Database2247698
RxListhttp://www.rxlist.com/cgi/generic/methdone.htm
Drugs.comhttp://www.drugs.com/methadone.html
WikipediaMethadone
ATC CodesN02AC52N07BC02R05DA06
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelshow(327 KB)
MSDSshow(60 KB)
Interactions
Drug Interactions
Drug
AlvimopanIncreases levels by receptor binding competition. Discontinue opioid administration at least 7 days prior to administrating Alvimopan.
AmobarbitalThe barbiturate, amobarbital, decreases the effect of methadone.
AmprenavirThe protease inhibitor, amprenavir, may decrease the effect of methadone.
AprobarbitalThe barbiturate, aprobarbital, decreases the effect of methadone.
ArtemetherAdditive QTc-prolongation may occur. Concomitant therapy should be avoided.
ButabarbitalThe barbiturate, butabarbital, decreases the effect of methadone.
ButalbitalThe barbiturate, butalbital, decreases the effect of methadone.
ButethalThe barbiturate, butethal, decreases the effect of methadone.
CarbamazepineCarbamazepine may decrease the serum level of methadone. Monitor for changes in the therapeutic and adverse effects of methadone if carbamazepine is initiated, discontinued or dose changed.
CimetidineCimetidine, a moderate CYP3A4 inhibitor, may increase the serum concentration of metahdone, a CYP3A4 substrate. Monitor for changes in the therapeutic and adverse effects of methadone if cimetidine is initiatied, discontinued or dose changed.
Dihydroquinidine barbiturateThe barbiturate, dihydroquinidine barbiturate, decreases the effect of methadone.
EfavirenzEfavirenz may decrease the serum concentration of methadone by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of methadone if efavirenz is initiated, discontinued or dose changed.
EltrombopagIncreases levels of Methadone via metabolism decrease. UDP-glucuronosyltransferase inhibition with unclear significance.
EthotoinThe hydantoin decreases the effect of methadone
EtravirineMethadone, when used concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor methadone therapy for decrease effectiveness and symptoms of withdrawal.
FluvoxamineFluvoxamine increases the effect and toxicity of methadone
FosamprenavirThe protease inhibitor, fosamprenavir, may decrease the effect of methadone.
FosphenytoinThe hydantoin decreases the effect of methadone
HeptabarbitalThe barbiturate, heptabarbital, decreases the effect of methadone.
HexobarbitalThe barbiturate, hexobarbital, decreases the effect of methadone.
LumefantrineAdditive QTc-prolongation may occur. Concomitant therapy should be avoided.
MephenytoinThe hydantoin decreases the effect of methadone
MethohexitalThe barbiturate, methohexital, decreases the effect of methadone.
MethylphenobarbitalThe barbiturate, methylphenobarbital, decreases the effect of methadone.
NelfinavirNelfinavir decreases the effect of methadone
NevirapineThe antiretroviral agent decreases the effect of methadone
PentobarbitalThe barbiturate, pentobarbital, decreases the effect of methadone.
PhenobarbitalThe barbiturate, phenobarbital, decreases the effect of methadone.
PhenytoinThe hydantoin decreases the effect of methadone
PrimidoneThe barbiturate, primidone, decreases the effect of methadone.
Quinidine barbiturateThe barbiturate, quinidine barbiturate, decreases the effect of methadone.
RifabutinThe rifamycin decreases the effect of methadone
RifampicinThe rifamycin decreases the effect of methadone
RifapentineThe rifamycin decreases the effect of methadone
RilpivirineDose adjustment and clinical monitoring of rilpivirine may be necessary if coadministered with methadone.
RitonavirThe protease inhibitor, ritonavir, may decrease the effect of methadone.
SecobarbitalThe barbiturate, secobarbital, decreases the effect of methadone.
St. John's WortSt. John's Wort decreases levels/effect of methadone
TacrolimusAdditive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
TalbutalThe barbiturate, talbutal, decreases the effect of methadone.
TamoxifenMethadone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
TamsulosinMethadone, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Methadone is initiated, discontinued, or dose changed.
TelaprevirTelaprevir decreases exposure of methane by 30% however opioid withdrawal was not observed in patients.
TelithromycinTelithromycin may reduce clearance of Methadone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Methadone if Telithromycin is initiated, discontinued or dose changed.
ThiopentalThiopental may decrease the effect of Methadone by increasing Methadone metabolism. Methadone withdrawal may occur.
ThiothixeneMay cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration.
TipranavirTipranavir, co-administered with Ritonavir, decreases the Methadone concentration. Monitor for symptoms of opiate withdrawal.
ToremifeneAdditive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.
TramadolMethadone may decrease the effect of Tramadol by decreasing active metabolite production.
TrimipramineAdditive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.
TriprolidineThe CNS depressants, Triprolidine and Methadone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy.
VoriconazoleVoriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of methadone by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of methadone if voriconazole is initiated, discontinued or dose changed.
VorinostatAdditive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
ZidovudineMethadone increases the effect and toxicity of zidovudine
ZiprasidoneAdditive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.
ZuclopenthixolAdditive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Food Interactions
  • Take without regard to meals. Avoid alcohol. Usually diluted in fruit juice.

Targets

1. Mu-type opioid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Mu-type opioid receptor P35372 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G: Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002 Apr;19(4):459-60. Pubmed
  4. Kakko J, von Wachenfeldt J, Svanborg KD, Lidstrom J, Barr CS, Heilig M: Mood and Neuroendocrine Response to a Chemical Stressor, Metyrapone, in Buprenorphine-Maintained Heroin Dependence. Biol Psychiatry. 2007 Sep 10;. Pubmed
  5. Kvam TM, Baar C, Rakvag TT, Kaasa S, Krokan HE, Skorpen F: Genetic analysis of the murine mu opioid receptor: increased complexity of Oprm gene splicing. J Mol Med. 2004 Apr;82(4):250-5. Epub 2004 Jan 9. Pubmed

2. Glutamate receptor ionotropic, NMDA 3A

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Glutamate receptor ionotropic, NMDA 3A Q8TCU5 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed
  3. Sotgiu ML, Valente M, Storchi R, Caramenti G, Biella GE: Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res. 2009 Oct;60(4):284-90. Epub 2009 Apr 11. Pubmed

3. Neuronal acetylcholine receptor subunit alpha-10

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Neuronal acetylcholine receptor subunit alpha-10 Q9GZZ6 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

4. Delta-type opioid receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: agonist

Components

Name UniProt ID Details
Delta-type opioid receptor P41143 Details

References:

  1. Gross ER, Hsu AK, Gross GJ: Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg. 2009 Nov;109(5):1395-402. Pubmed

5. 5-hydroxytryptamine receptor 3A

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: antagonist

Components

Name UniProt ID Details
5-hydroxytryptamine receptor 3A P46098 Details

References:

  1. Deeb TZ, Sharp D, Hales TG: Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone. Mol Pharmacol. 2009 Apr;75(4):908-17. doi: 10.1124/mol.108.053322. Epub 2009 Jan 8. Pubmed

Enzymes

1. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor inducer

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  4. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. Pubmed

2. Cytochrome P450 2C19

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C19 P33261 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 3A5

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A5 P20815 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

4. Cytochrome P450 3A7

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A7 P24462 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.

5. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

6. Cytochrome P450 2B6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2B6 P20813 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed
  4. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. Pubmed

7. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

8. Cytochrome P450 19A1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 19A1 P11511 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

9. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

10. Cytochrome P450 2C18

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C18 P33260 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

11. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Stormer E, Perloff MD, von Moltke LL, Greenblatt DJ: Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab Dispos. 2001 Jul;29(7):954-6. Pubmed
  2. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. Epub 2009 Nov 4. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:09